Data compiled by Redley Lamar · ChainSifter Intelligence
2Suppliers
6Customers
3Debt Items
0Related Chains
Source-Backed Evidence Depth
Invivyd, Inc. (IVVD) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
12Total relationships
2Distinct source URLs
11High confidence
0.887Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Invivyd, Inc. Suppliers
Ticker
Name
Confidence
Evidence
3PL-AGENT
3PL-AGENT
92%
We have entered a third-party logistics distribution agreement (the “3PL Agreement”) with a distribution agent (the “3PL Agent”) that distributes our product to our end customers.
WUXI-BIOLOGICS
WUXI-BIOLOGICS
92%
We have contracted with WuXi Biologics for the manufacturing of commercial-scale PEMGARDA and VYD2311.
Invivyd, Inc. Customers
Ticker
Name
Confidence
Evidence
HEALTHCARE-PROVIDERS
HEALTHCARE-PROVIDERS
92%
During the year ended December 31, 2025, our net product revenue was generated from sales to third-party specialty distributors and directly to a small number of infusion centers, healthcare provider…
INFUSION-CENTERS
INFUSION-CENTERS
92%
During the year ended December 31, 2025, our net product revenue was generated from sales to third-party specialty distributors and directly to a small number of infusion centers, healthcare provider…
PROVIDER-INSTITUTIONS
PROVIDER-INSTITUTIONS
92%
During the year ended December 31, 2025, our net product revenue was generated from sales to third-party specialty distributors and directly to a small number of infusion centers, healthcare provider…
THIRD-PARTY-SPECIALTY-DISTRIBUTORS
THIRD-PARTY-SPECIALTY-DISTRIBUTORS
92%
During the year ended December 31, 2025, our net product revenue was generated from sales to third-party specialty distributors and directly to a small number of infusion centers, healthcare provider…
ONE-DIRECT-CUSTOMER
ONE-DIRECT-CUSTOMER
90%
As of March 31, 2026, the Company recorded an allowance for doubtful accounts of $0.3 million related to one direct customer.
ADIMAB-LLC
ADIMAB-LLC
62%
late to rights conveyed by Adimab, LLC ( “ Adimab ” ) (see Note 7). The Company could experience delays in the development and commercialization of its product candidates and programs if the Adimab a…
Invivyd, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
IVVD-DEBT-10402
Warrants outstanding: 3.48
90%
xbrl warrant detail from xbrl 2026-03-31.
IVVD-DEBT-10403
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-12-31.
IVVD-DEBT
Debt stack $8.6M
90%
Market cache reports total debt of $8.6M.
Invivyd, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Invivyd, Inc..
Invivyd, Inc. Ownership
Holder
Name
Confidence
Evidence
IVVD-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 143 tracked holders.
Invivyd, Inc. Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.
